Quick Answer
BIOCRYST PHARMACEUTICALS INC reported Research And Development Expense of $166.13 million for the year ending 2025.
- BIOCRYST PHARMACEUTICALS INC showed a decrease of -4.9% in Research And Development Expense from 2024 to 2025.
- This data is from BIOCRYST PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), BIOCRYST PHARMACEUTICALS INC's Research And Development Expense has grown by 125.5%.
- Historical annual values: Fiscal year 2025: $166.13 million | Fiscal year 2024: $174.64 million | Fiscal year 2023: $216.57 million | Fiscal year 2022: $253.30 million | Fiscal year 2021: $208.81 million | Fiscal year 2020: $122.96 million | Fiscal year 2019: $107.07 million | Fiscal year 2018: $84.89 million | Fiscal year 2017: $66.96 million | Fiscal year 2016: $61.01 million | Fiscal year 2015: $72.76 million | Fiscal year 2014: $51.80 million | Fiscal year 2013: $41.94 million | Fiscal year 2012: $49.16 million | Fiscal year 2011: $57.25 million | Fiscal year 2010: $83.90 million | Fiscal year 2009: $73.66 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: